Long-term effects of dalfampridine in patients with multiple sclerosis

Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment par...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the neurological sciences Vol. 337; no. 1-2; pp. 18 - 24
Main Authors:	Ruck, T., Bittner, S., Simon, O.J., Göbel, K., Wiendl, H., Schilling, M., Meuth, S.G.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15.02.2014
Subjects:	4-Aminopyridine - therapeutic use Cognition Disorders - drug therapy Cognition Disorders - etiology Dalfampridine Disability Evaluation Drug Delivery Systems Electroencephalography Evoked Potentials - drug effects Evoked Potentials - physiology Fatigue Female Follow-Up Studies Humans Long-term treatment Male Middle Aged Mobility Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neurology Potassium Channel Blockers - therapeutic use Severity of Illness Index Statistics, Nonparametric Time Factors Walking - physiology Walking ability Mobility Fatigue Dalfampridine Long-term treatment MS Walking ability
ISSN:	0022-510X, 1878-5883, 1878-5883
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!